Sugi Predict

Sugi Predict / Compounds / SCHEMBL879216

SCHEMBL879216

SCHEMBL879216

CCOC(=O)c1ccc(CC)nc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 3/20 0.53
▸ CA1 P00915 3/20 0.53
▸ CA2 P00918 3/20 0.53
▸ CA7 P43166 3/20 0.53
▸ CA9 Q16790 3/20 0.53
▸ CA14 Q9ULX7 3/20 0.53
▸ ESR1 P03372 1/20 0.53
▸ ESR2 Q92731 1/20 0.53
▸ LMNA P02545 2/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ CYP3A4 P08684 1/20 0.51
▸ MAOA P21397 1/20 0.51
▸ TLR4 O00206 1/20 0.48
▸ TLR2 O60603 1/20 0.48
▸ RAB9A P51151 2/20 0.48
▸ MAPT P10636 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ HPGD P15428 4/20 0.46
▸ HTT P42858 2/20 0.46
▸ P2RY12 Q9H244 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2772711 0.88 CA12 (0.51) CA12CA1CA2CA7CA9
SCHEMBL7930158 0.87 LMNA (0.53) CA12CA1CA2CA7CA9
SCHEMBL17921366 0.87 L3MBTL1 (0.46) CA12CA1CA2CA7CA9
SCHEMBL1287501 0.87 CA12 (0.50) CA12CA1CA2CA7CA9
SCHEMBL9529349 0.87 CA12 (0.50) CA12CA1CA2CA7CA9
SCHEMBL9446767 0.85 CA12 (0.49) CA12CA1CA2CA7CA9
SCHEMBL22912516 0.85 CA12 (0.53) CA12CA1CA2CA7CA9
SCHEMBL18940424 0.85 CA12 (0.49) CA12CA1CA2CA7CA9
SCHEMBL18940470 0.85 CA12 (0.53) CA12CA1CA2CA7CA9
Hydrochloric Acid SCHEMBL9901295 0.85 LMNA (0.51) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188032-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND USES THEREOF BNH RESEARCH CO., LTD. (KR) 2025-06-12 — — US disclosed
US-12227507-B2 Pharmaceutical compounds PFIZER INC. (US) 2025-02-18 — — US disclosed
CN-119421876-A Compounds and medicaments as DDR1 kinase inhibitors 日本新药株式会社 2025-02-11 — — CN disclosed
EP-4501910-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND USES THEREOF BNH Research Co., Ltd. (KR) 2025-02-05 — — EP disclosed
CN-119255981-A Nitrogen-containing heterocyclic compound and use thereof BNH研究有限责任公司 2025-01-03 — — CN disclosed
CN-114555604-B Pharmaceutical compounds 辉瑞公司 2024-11-15 — — CN disclosed
WO-2023191468-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND USES THEREOF 주식회사 비엔에이치리서치 2023-10-05 — — WO disclosed
US-11634425-B2 Pharmaceutical compounds PFIZER INC. (US) 2023-04-25 — — US disclosed
US-20220324873-A1 PHARMACEUTICAL COMPOUNDS PFIZER INC. 2022-10-13 — — US disclosed
US-20220306639-A1 PHARMACEUTICAL COMPOUNDS PFIZER INC. 2022-09-29 — — US disclosed
US-20120108567-A1 Thiazolyl-Dihydro-Indazoles BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-03 — — US disclosed
EP-1951690-B1 HETEROCYCLIC CETP INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2012-03-28 — — EP disclosed
US-20110118208-A1 Thiazolyl-Dihydro-Indazoles BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-05-19 — — US disclosed
US-7888376-B2 Cholesteryl ester transfer protein (CETP) inhibitors; atherosclerosis and cardiovascular diseases; N-(1-(5-chloropyridin-2-yl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-4-(trifluoromethyl)thiazol-2-amine; Alzheimer's, atherosclerosis, venous thrombosis, peripheral vascular disease BRISTOL-MYERS SQUIBB COMPANY (US) 2011-02-15 — — US disclosed
EP-2280982-A1 THIAZOLYL-DIHYDRO-INDAZOLES Boehringer Ingelheim International GmbH (DE) 2011-02-09 — — EP disclosed
US-20100041717-A1 N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES BRISTOL-MYERS SQUIBB COMPANY (US) 2010-02-18 — — US disclosed
US-7652023-B2 Heterocyclic CETP inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-01-26 — — US disclosed
WO-2009112565-A1 THIAZOLYL-DIHYDRO-INDAZOLES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-17 — — WO disclosed
US-20070161685-A1 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-07-12 — — US disclosed
WO-1996006070-A1 DISUBSTITUTED ARYL AND HETEROARYL IMINES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY ALLERGAN (US) 1996-02-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161685-A1 HETEROCYCLIC CETP INHIBITORS CETP, CES1, NPC1 CA12 3900/4885CA1 4507/4885CA2 3976/4885
US-12227507-B2 Pharmaceutical compounds CHRNA6, GABRA6, CHRNA7 CA12 1900/4885CA1 2587/4885CA2 1650/4885
US-20100041717-A1 N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES CETP, APOB, CES1 CA12 4816/4885CA1 4851/4885CA2 4620/4885
US-20120108567-A1 Thiazolyl-Dihydro-Indazoles MKI67, CYP11B1, IGF1R CA12 3826/4885CA1 4000/4885CA2 2253/4885
US-20110118208-A1 Thiazolyl-Dihydro-Indazoles MKI67, CYP11B1, IGF1R CA12 3826/4885CA1 4000/4885CA2 2253/4885
US-20250188032-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND USES THEREOF NLN, GRIN1, GRIN2A CA12 2349/4885CA1 393/4885CA2 2998/4885
US-11634425-B2 Pharmaceutical compounds GABRA6, CHRNA6, CNR1 CA12 1729/4885CA1 2643/4885CA2 1515/4885
US-20220306639-A1 PHARMACEUTICAL COMPOUNDS CHRNA6, GABRA6, CHRNA7 CA12 1900/4885CA1 2587/4885CA2 1650/4885
US-20220324873-A1 PHARMACEUTICAL COMPOUNDS GABRA6, CNR1, CHRNA6 CA12 1866/4885CA1 2610/4885CA2 1441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.